British Journal of Cancer

Article	Citations
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	194
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours	178
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	154
Advancing radiomics from contrast-enhanced mammography in breast cancer	147
Correction to: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort	141
Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients	119
Correction: Wnt/ERK/CDK4/6 activation in the partial EMT state coordinates mammary cancer stemness with self-renewal and inhibition of differentiation	118
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	116
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	107
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	103
Navigating therapeutic strategies: HPV classification in head and neck cancer	102
Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis	101
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours	100
Metabolic adaptations in prostate cancer	100
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	99
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	95
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours	93
Metastasis-associated fibroblasts in peritoneal surface malignancies	91
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer	90
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	88
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	88
CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles	85
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	80
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3	80
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	80

Years of life lost due to cancer in the United Kingdom from 1988 to 2017	79
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	78
Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways	77
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	76
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	75
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	73
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	72
Assessments of social vulnerability on laryngeal cancer treatment & prognosis in the US	70
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	70
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	70
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	69
Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians	68
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analy	68
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	68
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	66
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	65
Genomic ALK alterations in primary and relapsed neuroblastoma	65
Identification of increased dedifferentiation along the Prom1+ cancer cells in Müllerian adenosarcoma with sarcomatous overgrowth	63
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	63
Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme	62
Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma	61
Hypoxia- and Postirradiation reoxygenation-induced HMHA1/ARHGAP45 expression contributes to cancer cell invasion in a HIF-dependent manner	61
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study	61
Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors	60
Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England	59
The impact of the first 2 years of the COVID-19 pandemic on breast cancer diagnoses: a population-based study in England	59
Optimizing adjuvant treatment strategies for non-pancreatic periampullary cancers	58
Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial	56
Serum 25-hydroxyvitamin D concentrations and colorectal cancer incidence in adults with type 2 diabetes	56
SLC7A11-AS1 contributes to prolonged activation of activin A/Smad signaling by suppressing PPM1A myristoylation in pancreatic cancer	55
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer	54
Adolescent dietary patterns in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study	53
Emerging nanomedical strategies for direct targeting of pediatric and adult diffuse gliomas	53
Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma	52
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II st	50
Cancer in Costello syndrome: a systematic review and meta-analysis	50
Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20	49
Progress and priorities in reducing the time to cancer diagnosis	49
Effect of risk-based screening for upper gastrointestinal cancers: a multi-center real-world study	48
Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: a prospective cohort study	48
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer	47
A systematic review of microbial markers for risk prediction of colorectal neoplasia	47
Multistate models for the natural history of cancer progression	46
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer	46
Nutritional status, body composition and chemotherapy dosing in children and young people with cancer: a systematic review by the SIOP nutrition network	46
Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer	46
Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England	46
Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis	45
PTBP1 drives c-Myc-dependent gastric cancer progression and stemness	45
Retraction Note: Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis	45

Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma	44
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors	44
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification	43
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study	43
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer	43
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer	43
The Glasgow Microenvironment Score and risk and site of recurrence in TNM I–III colorectal cancer	43
Editorial Expression of Concern: Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-	42
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination	42
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer	42
Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study	42
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials	42
EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia	41
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)	40
Correction: Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes	40
Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic	40
High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade	40
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy	40
Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin	40
Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications	40
Routes to diagnosis for hepatocellular carcinoma patients: predictors and associations with treatment and mortality	39
Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England	39
Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28	39
Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case–control study	38
The mediating role of combined lifestyle factors on the relationship between education and gastric cancer in the Stomach cancer Pooling (StoP) Project	38
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial	38
Correction: Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	38
Oesophageal cancer awareness and anticipated time to help-seeking: results from a population-based survey	38
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer	37
Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer	37
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients	37
The in vitro dynamics of pseudo-vascular network formation	37
Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/ IL-23 axis	37
A multimodal imaging study to highlight elastin-derived peptide pro-tumoral effect in a pancreatic xenograft model	37
MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling	37
What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study	36
Population-based nasopharyngeal carcinoma survival in southern China	36
Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets	36
Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma	36
50 years on and still very much alive: ‘Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics’	36
Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial	36
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions	35
Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer	35
Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM inhibits CD8+ T cell infiltration	35
Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway	35
Correction to: Methyl-CpG-binding domain 3 inhibits epithelial–mesenchymal transition in pancreatic cancer cells via TGF-β/Smad signalling	35
Benchmarking standard-of-care and emerging genomic approaches to enhance diagnosis in pediatric acute lymphoblastic leukemia	35
Deciphering the central role of TMOD2 in colorectal cancer progression and metastasis	35
The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review	34
Manassantin A inhibits tumour growth under hypoxia through the activation of chaperone-mediated autophagy by modulating Hsp90 activity	34
Capturing breast cancers’ copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond	34
Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases	34
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer	34
A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses’ Health Studies	34
Correction: Modelled mortality benefits of multi-cancer early detection screening in England	34
Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer	34
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers	34
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study	34
Cancer risk in individuals with polydactyly: a Swedish population-based cohort study	34
Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions	34
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia	34
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer	34
Confidence bands in survival analysis	33
UK Biobank: a globally important resource for cancer research	33
Immune checkpoint inhibitor combinations—current and emerging strategies	33
Sodium nitrite orchestrates macrophage mimicry of tongue squamous carcinoma cells to drive lymphatic metastasis	33
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors	33
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis	33
Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients	33
Consultations for clinical features of possible cancer and associated urgent referrals before and during the COVID-19 pandemic: an observational cohort study from English primary care	33
The role of genetic predisposition in cardiovascular risk after cancer diagnosis: a matched cohort study of the UK Biobank	33
Glycometabolic reprogramming-mediated proangiogenic phenotype enhancement of cancer-associated fibroblasts in oral squamous cell carcinoma: role of PGC-1α/PFKFB3 axis	33
Thinking inside the box: intracellular roles for complement system proteins come into focus	33
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours	33
Regulatory non-coding somatic mutations as drivers of neuroblastoma	33
Stroma AReactive Invasion Front Areas (SARIFA) and the tumour immune microenvironment in colorectal cancer	32
Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation	32
DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance	32
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status	32
Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England	32

Correction: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility	32
VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models	32
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma	32
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial	32
Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer	32
Hypoxia does not predict lack of benefit from adjuvant radiotherapy for patients with early stage breast cancer	32
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care	32
Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study	31
Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer	31
Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer	31
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk	31
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer	31
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations	31
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study	31
Breast cancer cell-derived adrenomedullin confers cancer-associated adipose remodeling through the cAMP/Creb1/Zeb1 axis	31
Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis	31
Galectin-9-driven immunosuppressive macrophage population shapes the lymph node metastatic microenvironment	30
Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up	30
HECTD3 regulates the tumourigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway	30
Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome	30
Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-γ-induced tumour-associated fibroblasts remodelling	30
Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination	30
Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology	30
Health benefits and harms of mammography screening in older women (75+ years)—a systematic review	30
Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy	30
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function	30
EIF4A3-negatively driven circular RNA β-catenin (circβ-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis	30
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing	30
Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer	29
Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer	29
Editorial Expression of Concern: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential	29
MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data	29
Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	29
CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer	29
Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090)	29
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma	29
The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research	29
Obituary – Margaret Wilcox	29
Role of 18F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?	28
Correction: DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer	28
ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer	28
Understanding genetic architecture of breast cancer: how can proteome-wide association studies contribute?	28
Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration	28
Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLC	28
Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer	27
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy	27
Hypoxia-inducible factor 3α1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis	27
Angiogenin and plexin-B2 axis promotes glioblastoma progression by enhancing invasion, vascular association, proliferation and survival	27
Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records	27
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies	27
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer	27
UDP-glucose ceramide glucosyltransferase promotes radioresistance via membrane reorganization to maintain redox balance in glioblastoma	27
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?	27
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis	27
Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study	26
Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer	26
Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis	26
AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma	26
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma	26
Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer	26
A study of subjective memory impairment in long-term testicular cancer survivors	26
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells	26
Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel–Lindau gene in the ccRCC	25
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2	25
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine	25
Attention-based deep learning for breast lesions classification on contrast enhanced spectral mammography: a multicentre study	25
Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition	25
The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance	25
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers	25
Prognostic value of post-operative iron biomarkers in colorectal cancer: population-based patient cohort	25
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)	25
Associations between serum glucose, insulin, insulin resistance and the risk of incident primary liver cancer or chronic liver disease mortality: a nested case–control study	25
Genome-wide polygenic risk scores for colorectal cancer have implications for risk-based screening	25
Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma	25
A liquid biopsy signature for predicting early recurrence in patients with gastric cancer	24
Modelled mortality benefits of multi-cancer early detection screening in England	24
Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus	24
Breast density is strongly associated with multiparametric magnetic resonance imaging biomarkers and pro-tumorigenic proteins in situ	24
Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase	24
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer	24
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients	24
Comment on: “Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial”	24
Intratumour heterogeneity, from hypothesis to the clinic	23
LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis	23
Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations throughout the life course and risk of colorectal cancer precursors	23
Correction: E2F7−EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression	23
Correction: TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory	23
HeLa cells cross-contaminated nasopharyngeal carcinoma cell lines: Still a common problem	23
PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours	23
Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs	23
Birthweight, height, and body mass index in relation to the expression of stem cell markers among women with benign breast biopsies in the Nurses’ Health Study II	23
Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study	23
Editorial Expression of Concern: Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21	23
Chemotherapy-induced neuropathy in monomethyl Auristatin E treatment: prevention by lithium	22
Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment	22